Press release
Pancreatic Adenocarcinoma Market Growth Projections 2023-2032: DelveInsight Analysis | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd, Carisma Therapeutics Inc, Cue Biopharma, Bold Therapeutics, Pur
DelveInsight's "Pancreatic Adenocarcinoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of Pancreatic Adenocarcinoma, historical and forecasted epidemiology as well as the Pancreatic Adenocarcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Pancreatic Adenocarcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pancreatic Adenocarcinoma Market Forecast
https://www.delveinsight.com/sample-request/pancreatic-adenocarcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Pancreatic Adenocarcinoma Market Report:
• The Pancreatic Adenocarcinoma market size was valued approximately and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In December 2024, Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced today that the pivotal Phase 3 PANOVA-3 trial achieved its primary endpoint, showing a statistically significant improvement in median overall survival (mOS) compared to the control. The PANOVA-3 trial assessed the use of Tumor Treating Fields (TTFields) therapy in combination with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.
• According to DelveInsight's estimates, the total incident cases of Pancreatic Adenocarcinoma in the United States accounted for approximately 35% in 2023.
• The 2023 analysis indicates that the highest stage-specific incident cases of Pancreatic Adenocarcinoma in the US were for distant stages, comprising nearly 50% of cases, followed by regional and localized stages.
• The mutation types associated with Pancreatic Adenocarcinoma include KRAS2, TP53, SMAD4/DPC4, BRCA1/2, MSI-H/dMMR, and NTRK. In the United States, KRAS2 and TP53 were responsible for the largest number of incident cases of Pancreatic Adenocarcinoma in 2023.
• Key Pancreatic Adenocarcinoma Companies: AstraZeneca, Merck Sharp & Dohme, Actuate Therapeutics, Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co.Ltd, Carisma Therapeutics Inc, Cue Biopharma, Bold Therapeutics, Purple Biotech Ltd, ENB Therapeutics, Gritstone bio, AstraZeneca, Candel Therapeutics, Alligator Bioscience, FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, and others
• Key Pancreatic Adenocarcinoma Therapies: LYNPARZA (olaparib), KEYTRUDA (pembrolizumab), Elraglusib (9 ING 41), DF 7001, TNG260, ATA 3271, CMG 901, CT-0508, CUE-102, BOLD-100, CM24, ENB-003, GRT-C903, AZD0171, CAN-2409, Mitazalimab, Pamrevlumab, NIS793, Masitinib, Glufosfamide, and others
• The Pancreatic Adenocarcinoma epidemiology based on gender analyzed that males are more commonly affected in case of Pancreatic Adenocarcinoma than females
Request a sample for the Pancreatic Adenocarcinoma Market Report:
https://www.delveinsight.com/report-store/pancreatic-adenocarcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Pancreatic Adenocarcinoma Overview
Pancreatic adenocarcinoma is the most common type of pancreatic cancer, originating in the exocrine cells of the pancreas. It is highly aggressive, often diagnosed at an advanced stage due to its asymptomatic early progression. Symptoms include jaundice, weight loss, abdominal pain, and digestive issues. Risk factors include smoking, chronic pancreatitis, diabetes, and genetic predisposition. Treatment options include surgery (such as the Whipple procedure), chemotherapy, radiation, and targeted therapies, but prognosis remains poor due to late detection and resistance to treatment.
Pancreatic Adenocarcinoma Epidemiology Segmentation:
The Pancreatic Adenocarcinoma market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Pancreatic Adenocarcinoma
• Prevalent Cases of Pancreatic Adenocarcinoma by severity
• Gender-specific Prevalence of Pancreatic Adenocarcinoma
• Diagnosed Cases of Episodic and Chronic Pancreatic Adenocarcinoma
Download the report to understand which factors are driving Pancreatic Adenocarcinoma epidemiology trends @ Pancreatic Adenocarcinoma Epidemiological Insights
https://www.delveinsight.com/sample-request/pancreatic-adenocarcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Pancreatic Adenocarcinoma Market
The dynamics of the Pancreatic Adenocarcinoma market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Niraparib, Dostarlimab, and others during the forecasted period 2019-2032.
Pancreatic Adenocarcinoma Therapies and Key Companies
• LYNPARZA (olaparib): AstraZeneca
• KEYTRUDA (pembrolizumab): Merck Sharp & Dohme
• Elraglusib (9 ING 41): Actuate Therapeutics
• DF 7001: Dragonfly Therapeutics CMG 901 Keymed B
• TNG260: Tango Therapeutics
• ATA 3271: Atara Biotherapeutics
• CMG 901: Keymed Biosciences Co.Ltd
• CT-0508: Carisma Therapeutics Inc
• CUE-102: Cue Biopharma
• BOLD-100: Bold Therapeutics
• CM24: Purple Biotech Ltd
• ENB-003: ENB Therapeutics
• GRT-C903: Gritstone bio
• AZD0171: AstraZeneca
• CAN-2409: Candel Therapeutics
• Mitazalimab: Alligator Bioscience
• Pamrevlumab: FibroGen
• NIS793: Novartis AG
• Masitinib: AB Science
• Glufosfamide: Eleison Pharmaceuticals
To know more about Pancreatic Adenocarcinoma treatment, visit @ Pancreatic Adenocarcinoma Medications
https://www.delveinsight.com/sample-request/pancreatic-adenocarcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Pancreatic Adenocarcinoma Market Drivers
• Advancements in computational and bioinformatics platforms and several other R&D practices enable the development of Pancreatic Adenocarcinoma
• Strong pipeline activity
Pancreatic Adenocarcinoma Market Barriers
• Rising incidence of cancer will provide a larger window of opportunity for new treatments
• Reoccurrence is very common in cancers even after proper treatment; this opens up a new window for pipeline activity
Scope of the Pancreatic Adenocarcinoma Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Pancreatic Adenocarcinoma Companies: AstraZeneca, Merck Sharp & Dohme, Actuate Therapeutics, Dragonfly Therapeutics CMG 901 Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co.Ltd, Carisma Therapeutics Inc, Cue Biopharma, Bold Therapeutics, Purple Biotech Ltd, ENB Therapeutics, Gritstone bio, AstraZeneca, Candel Therapeutics, Alligator Bioscience, FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, and others
• Key Pancreatic Adenocarcinoma Therapies: LYNPARZA (olaparib), KEYTRUDA (pembrolizumab), Elraglusib (9 ING 41), DF 7001, TNG260, ATA 3271, CMG 901, CT-0508, CUE-102, BOLD-100, CM24, ENB-003, GRT-C903, AZD0171, CAN-2409, Mitazalimab, Pamrevlumab, NIS793, Masitinib, Glufosfamide, and others
• Therapeutic Assessment: Pancreatic Adenocarcinoma current marketed and Pancreatic Adenocarcinoma emerging therapies
• Migraine Market Dynamics: Pancreatic Adenocarcinoma market drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Pancreatic Adenocarcinoma Market Access and Reimbursement
Discover more about therapies set to grab major Pancreatic Adenocarcinoma market share @ Pancreatic Adenocarcinoma Treatment Landscape
https://www.delveinsight.com/sample-request/pancreatic-adenocarcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Pancreatic Adenocarcinoma Market Report Introduction
2. Executive Summary for Pancreatic Adenocarcinoma
3. SWOT analysis of Pancreatic Adenocarcinoma
4. Pancreatic Adenocarcinoma Patient Share (%) Overview at a Glance
5. Pancreatic Adenocarcinoma Market Overview at a Glance
6. Pancreatic Adenocarcinoma Disease Background and Overview
7. Pancreatic Adenocarcinoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Pancreatic Adenocarcinoma
9. Pancreatic Adenocarcinoma Current Treatment and Medical Practices
10. Pancreatic Adenocarcinoma Unmet Needs
11. Pancreatic Adenocarcinoma Emerging Therapies
12. Pancreatic Adenocarcinoma Market Outlook
13. Country-Wise Pancreatic Adenocarcinoma Market Analysis (2019-2032)
14. Pancreatic Adenocarcinoma Market Access and Reimbursement of Therapies
15. Pancreatic Adenocarcinoma Market drivers
16. Pancreatic Adenocarcinoma Market barriers
17. Pancreatic Adenocarcinoma Appendix
18. Pancreatic Adenocarcinoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Pancreatic Adenocarcinoma Pipeline https://www.delveinsight.com/report-store/pancreatic-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Pancreatic Adenocarcinoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Pancreatic Adenocarcinoma market. A detailed picture of the Pancreatic Adenocarcinoma pipeline landscape is provided, which includes the disease overview and Pancreatic Adenocarcinoma treatment guidelines.
Pancreatic Adenocarcinoma Epidemiology https://www.delveinsight.com/report-store/pancreatic-adenocarcinoma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Pancreatic Adenocarcinoma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Pancreatic Adenocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
• Mammography Devices Market: https://www.delveinsight.com/report-store/mammography-devices-market
• Global Kinase Inhibitor Market: https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market-insight
• Nerve Repair And Regeneration Devices- Market Insights: https://www.delveinsight.com/report-store/nerve-repair-and-regeneration-market
• Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
• Diabetic Wound Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pancreatic Adenocarcinoma Market Growth Projections 2023-2032: DelveInsight Analysis | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd, Carisma Therapeutics Inc, Cue Biopharma, Bold Therapeutics, Pur here
News-ID: 3865719 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for Pancreatic
Growing Pancreatic Cancer Cases : Pivotal Factor Influencing Pancreatic Cancer D …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Pancreatic Cancer Drugs Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for pancreatic cancer drugs has seen consistent growth over the past few years. An escalation from $3.96 billion in 2024 to $4.1 billion in 2025 is projected, marking a compound annual…
Pancreatic Cancer Diagnostic Market Surges In Response To Escalating Prevalence …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Pancreatic Cancer Diagnostic Market Through 2025?
The market size for pancreatic cancer diagnostics has been witnessing robust growth in recent times. There will be a growth from $4.24 billion in 2024 to $4.55 billion in 2025, showcasing a Compound Annual Growth Rate…
Pancreatic Cancer Diagnostic Market Surges In Response To Escalating Prevalence …
The Pancreatic Cancer Diagnostic Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Pancreatic Cancer Diagnostic Market Size and Projected Growth Rate?
There has been a significant expansion in the pancreatic cancer diagnostic market recently. This market is projected to increase from a value…
Pancreatic Amylase Reagent Kits: Streamlining Enzyme Analysis for Efficient Panc …
Pancreatic Amylase Reagent Kits Market 2023 Forecast: Unveiling Opportunities and Growth
Pancreatic Amylase Reagent Kits Market research report helps to recognize the market challenges and opportunities. Global Pancreatic Amylase Reagent Kits Market report contains the recent forecast research for the predicted period. The report extensively offers the latest information about the technological developments and market growth prospect on the basis of the regional landscape. This Report offers a complete evaluation of…
Pancreatic Cancer Therapy Market: Rise in Number of Patients Suffering with Panc …
Pancreatic cancer is one of the aggressive cancers that originate in the tissues of the pancreas and rapidly spreads to the nearby organs. Pancreatic cancer is the 12th most commonly occurring cancer in the world. According to the American Cancer Society, ~55,440 patients in the US are expected to be diagnosed with pancreatic cancer in 2018. Moreover, the ACS also reports that pancreatic cancer is the third leading cause of…
Pancreatic Cancer Treatment
Pancreatic Cancer Treatment Market describes its growth, size, share, Forecast and trends to 2025
Pancreatic Cancer Treatment Market Production and Demand Analysis 2019 to 2025
Pancreatic Cancer Treatment Market 2019 Manufacturing Analysis and Development Forecast 2025
Pancreatic Cancer Treatment Market 2019: Recent Study Including Growth Factors, Regional Drivers, Forecast 2025
Pancreatic Market to Insight By 2025: Top Key Vendors
Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to…
